ETF午评 | 创新药板块全线反弹，标普生物科技ETF涨3.8%

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index down 0.24%, the Shenzhen Component Index down 1.07%, and the ChiNext Index down 1.58% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 12,702 billion yuan, an increase of 22 billion yuan compared to the previous day [1] - Over 4,000 stocks in the market experienced declines [1] Sector Performance - The oil and gas extraction and services, insurance, brain-computer interface, banking, and influenza sectors saw the largest gains [1] - Conversely, the photovoltaic equipment, cultivated diamonds, controllable nuclear fusion, phosphorus chemical, battery, military equipment, and photolithography concept stocks faced the most significant declines [1] ETF Performance - The innovative drug sector rebounded across the board, with the S&P Biotechnology ETF, Hong Kong Stock Connect Innovative Drug ETF, and NASDAQ Biotechnology ETF rising by 3.87%, 2.94%, and 2.86% respectively [1] - The Hong Kong Stock Connect medical ETFs, including the Fidelity and Huatai-PineBridge Innovative Drug ETFs, both increased by 2.75% [1] - The petrochemical sector also saw a rebound, with the Harvest Fund S&P Oil and Gas ETF rising by 1.95% [1] Photovoltaic Sector - The photovoltaic sector experienced a significant downturn, with the Kexin New Energy ETF, Photovoltaic ETF Index Fund, and Kexin Board New Energy ETF dropping by 5.91%, 5.82%, and 5.68% respectively [2] - The power grid sector followed suit, with the power grid equipment ETF declining by 3.11% and the power grid ETF down by 2.87% [2]